echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 29 large varieties with volume procurement hundreds of pharmaceutical companies to fight the price (with list)

    29 large varieties with volume procurement hundreds of pharmaceutical companies to fight the price (with list)

    • Last Update: 2021-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Henan Province with volume procurement, 241 pharmaceutical companies began to fight prices.
    1, Henan belt procurement, will start bidding Henan Province for 29 commonly used large varieties of strip procurement ushered in the latest progress, by expert review, a total of 241 pharmaceutical companies meet the declaration requirements, will further around the price of competitive bidding.
    Recently, Henan Province issued "on the publicity of our province's drug centralized belt procurement related qualification expert evaluation results notice", in the annex section at the same time published "Henan Province drug collection enterprise qualification evaluation results" and "Henan Province drug collection economic and technical evaluation results."
    According to the notice, the above results will be made public on December 16th-December 18th (i.e. today), which means that qualified pharmaceutical companies will enter a follow-up bidding process, which is expected to be mainly a price match.
    According to Saibai Blue combing, Henan Province's current round of volume procurement, involving a total of omerazole, table jubby star, Kawakubo, Gissytabin, Lansolazine, sodium heparin, curk lutein, bromine has been new and other 29 commonly used large varieties.
    May be due to the involvement of large clinical varieties, Henan Province, the current round of collection attracted 252 pharmaceutical companies to participate - according to Cypress Blue combing, of which 241 pharmaceutical companies meet the declaration requirements, and 11 pharmaceutical companies for reasons such as unclassified, not uploaded materials, not provided "drug business license" and other reasons, was found not to meet the declaration requirements.
    pharmaceutical companies involved in this round of volume procurement in Henan Province are: AstraZeneca, Fessen Yuscabi, China Resources Shuanghe, Beijing Four Rings Pharmaceuticals, North China Pharmaceuticals, Pfizer, Jiangsu Hengrui, Jichuan Pharmaceuticals, Jiangsu Haussen, Jiangsu Kangyuan, Zhengda Tianqing, Nanjing Xiansheng, Qilu Pharmaceuticals, National Pharmaceutical Group, Chenxin Pharmaceuticals, Shandong Luoxin, Yangzijiang, Shi Medicine, Shanghai Pharmaceuticals, Haiske, Lepu, Hanyu Pharmaceuticals and many other well-known pharmaceutical companies.
    , according to Cypress Blue combing, Henan this round of volume procurement, in the economic and technical standard link of the evaluation results a total of 463.
    In accordance with the provisions of the Henan Provincial Drug Concentration And Volume Purchase Document issued by Henan Medical Insurance Bureau and Henan Provincial Public Resources Trading Center, Henan Province adopted a comprehensive evaluation method to confirm the results of the current round of collection, specifically, the comprehensive evaluation score, the economic and technical standard score accounted for 60%, the business standard score accounted for 40%.
    In which the economic and technical standards are by experts in accordance with the relevant indicators of the enterprise declaration data score - mainly, drug qualification evaluation (divided into 3 grades, original research drugs, reference preparations, over-consistent evaluation of generic drugs, etc. scored the highest score of 25 points), comprehensive evaluation of drug quality (a total of 40 points, Mainly examine the relevant substances, adaptive disorders, expiration date, drug supply routes, storage conditions, injections will also take into account dosage forms and packaging materials), enterprise qualification evaluation (15 points, mainly look at industry rankings), sales and supply evaluation (20 points, inspection indicators are mainly raw materials and medical institutions coverage).
    , in the current economic and technical evaluation process is mainly to examine the above indicators, can basically be regarded as the supply strength between pharmaceutical companies and product quality competition.
    Business standard is mainly, in accordance with the existing margin principle, do not take into account the difference in dosage form and packaging materials, the conversion to the minimum main product price - according to the provisions, the lowest business list price of the same group as the base price, the score is 100, the other declared enterprises business standard score (base price / business price) ×100 - that is, under the premise of the benchmark price unchanged, the higher the business list price of other enterprises, the lower the score in this one.
    Enterprises in this link of the score, mainly affected by two factors, on the one hand, is the lowest price (this and 1.8 times the mechanism is similar, but did not let the relevant enterprises out of the provisions);
    After the economic and technological standards into the commercial standard link, will be the price competition between pharmaceutical companies, and then the recruitment department will be based on the results of the comprehensive review to determine the selected enterprises - in short, product quality, supply capacity, as well as the price of pharmaceutical companies will jointly determine the final performance of more than 240 pharmaceutical companies in this Henan province-level collection.
    In accordance with the provisions of the Henan harvesting scheme, each variety of up to two enterprises selected - "the same group of declared enterprises in 3 or more, to take a comprehensive evaluation of the way to determine the proposed enterprises;
    However, the comprehensive review is mainly a price and quality competition between pharmaceutical companies, and the essence of bargaining negotiations is still around price - according to the provisions of the collection scheme, mainly based on the average reduction of all the proposed drugs of the comprehensive review team, the price reduction of the negotiated drugs is not lower than the above-mentioned benchmark, confirm the proposed selection;
    2, the common pattern of provincial collection gradually surfaced in fact, economic and technical standards and commercial standards comprehensive evaluation of the bidding method in the provincial collection, more and more common - for example, Jiangxi, Shandong and other provinces in the province's volume procurement, have adopted the economic and technical standards and business standards comprehensive evaluation of the way.
    Take the relevant aspects of the more optimistic Jiangxi model, according to Saibai Blue combing, Jiangxi model is mainly characterized by: to adopt a comprehensive evaluation of the way, the evaluation indicators are divided into two parts - one is a business standard, one is an economic and technical standard.
    Economic standards are mainly divided into drug quality levels, drug quality inspection, enterprise registration standards, industry ranking, medical institutions coverage, distribution rate, distribution methods and other indicators, and Jiangxi regulations, economic and technical standards score below 70, directly eliminated;
    According to Saibai Blue incomplete combing, Hebei, Anhui, Fujian, Hubei, Hunan, Guangxi, Qinghai, Henan, Zhejiang, Jiangsu, Jiangxi, Shandong and other provinces have some of the purchase of higher amounts of drugs, clinical use of large provincial collection.
    it is not difficult to see that with the increase in the number of areas to carry out provincial harvesting, as well as the frequency of provincial harvesting, the collection programmes between different provinces began to reflect a clear mutual impact, cross-cutting.
    For example, Henan Province this time the tender pharmaceutical companies are divided into A, B two groups - the original research drugs, compared preparations, through the quality and efficacy of consistent evaluation of generic drugs, according to the new registration classification approved generic drugs and drugs included in the "China Listed Drugs List" as Group A;
    For bidding pharmaceutical companies according to the level of product quality grouping should still be said to have a greater impact on the final bidding pattern and results - for example, from Henan Province, the comprehensive evaluation results of the economic and technical standards can be seen that the number of Group B pharmaceutical companies far more than the number of Group A pharmaceutical companies, and even some varieties of Group A, only one pharmaceutical company.
    according to the incomplete statistics of Cypress Blue, Jiangxi, Shandong, Zhejiang and other provinces have adopted the drug companies into different bidding groups of recruitment strategy, and this group trend is becoming more and more obvious.
    on the basis of the drug companies divided into A and B groups, Henan Province's collection and harvesting program also requires - Group A of the selected varieties agreed procurement volume by reference to medical institutions to report 70% of the group's demand to determine.
    if Group A has no selected enterprise, the group purchase amount is assigned to Group B.
    In Zhejiang Province, there are similar provisions in the collection documents - such as A, B in any group of streaming standards, then the group agreed to purchase 50% into another group of agreed procurement volume, the remaining 50% as the agreed procurement volume of the remaining amount - some analysts pointed out that similar measures can put more pressure on pharmaceutical companies in Group A to reduce prices, to prevent their negative quotation attitude.
    in addition to the above information, Henan Province this time with the volume of procurement there are some bright spots worthy of attention, such as on the issue of national and provincial mining cross, Henan Province on the provisions - "in the implementation process, the state organization of drug centralized procurement varieties and the provincial centralized procurement there is a cross, if the selected enterprises are the same, the national and provincial centralized procurement compared to the low price supply to the province, until the end of the procurement cycle."
    if the selected enterprises are different, the results of the provincial election will still be implemented, and the results of the provincial procurement cycle shall be implemented."
    In addition, Henan also stipulates that non-selected and similar alternative drugs will be included in the scope of key monitoring;
    as for the current round of drug collection in Henan Province, the final results and product decline, I believe it will not be long before there will be an answer.
    : Henan belt procurement enterprise qualification evaluation results
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.